- Previous Close
0.0011 - Open
0.0010 - Bid --
- Ask --
- Day's Range
0.0010 - 0.0010 - 52 Week Range
0.0001 - 0.0153 - Volume
1,000,000 - Avg. Volume
63,076 - Market Cap (intraday)
2.145M - Beta (5Y Monthly) 0.44
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Quia Pharma AB (publ) engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform. The company develops drugs through its pegylation technology platform. Its product pipeline includes QPG-1030 (pegylated teduglutide) for the treatment of short bowel syndrome, and QPG-1029 under pre-clinical development for stable plasma concentration, as well as antibody-drug conjugates being developed using the company's Uni-Qleaver technology-platform. The company was formerly known as QuiaPEG Pharmaceuticals Holding AB (publ) and changed its name to Quia Pharma AB (publ). Quia Pharma AB (publ) was founded in 2004 and is headquartered in Uppsala, Sweden.
www.quiapeg.comRecent News: 99B0.F
View MorePerformance Overview: 99B0.F
Trailing total returns as of 12/20/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 99B0.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 99B0.F
View MoreValuation Measures
Market Cap
2.23M
Enterprise Value
2.00M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.77
Price/Book (mrq)
0.49
Enterprise Value/Revenue
9.77
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-277.59%
Return on Assets (ttm)
-25.27%
Return on Equity (ttm)
-63.90%
Revenue (ttm)
4.99M
Net Income Avi to Common (ttm)
-13.86M
Diluted EPS (ttm)
-0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
2.58M
Total Debt/Equity (mrq)
9.59%
Levered Free Cash Flow (ttm)
-27.09M